{'fraction_non_alphanumeric': 0.029580152671755726, 'fraction_numerical': 0.0, 'mean_word_length': 5.098837209302325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation and management of glaucoma after keratoprosthesis

Purpose of review To review the causes and treatment of glaucoma in Boston keratoprosthesis (K-pro) recipients. Recent findings Glaucoma exists in up to three-quarters of patients who undergo K-pro surgery. After K-pro placement, intraocular pressure (IOP) is measured by digital palpation, which has been found to be reliable in trained observers. The onset or progression of glaucoma in K-pro patients should be monitored through visual field testing, direct visualization and structural imaging of the optic nerve. Although medical therapy is an option, one-half to three-quarters of K-pro recipients are surgically managed with a glaucoma drainage device (GDD) or, less commonly, cyclophotocoagulation. Summary Glaucoma is a common and permanent blinding sequelae of K-pro surgery. In K-pro patients, elevated IOP and changes in the optic nerve head should result in a high index of suspicion for glaucoma. Management is frequently surgical and typically entails placement of a GDD.